Claims
- 1. A method for inducing ocular tissue regeneration, comprising administering to a subject in need thereof and effective amount of an ocular tissue regeneration inducer, which comprises, as an active ingredient, a hydrophilic polymer mainly composed of monomeric units selected from the group consisting of alkylene glycol units, vinyl monomeric units having a nondissociating hydrophilic group, and mixtures thereof.
- 2. The method of claim 1, wherein said nondissociating hydrophilic group is selected from the group consisting of a hydroxyl group, an amide bond, and an acid anhydride group.
- 3. The method of claim 1, wherein said hydrophilic polymer is a polymer mainly composed of monomeric units selected from the group consisting of alkylene glycol units, vinyl alcohol units, N-vinyllactam units, and mixtures thereof.
- 4. The method of claim 1, wherein said hydrophilic polymer is a polymer mainly composed of monomeric units derived from monomers selected from the group consisting of ethylene glycol, propylene glycol, vinyl alcohol, 2-hydroxyethyl (meth)acrylate, 2-hydroxypropyl (meth)acrylate, 3-hydroxypropyl (meth)acrylate, 2,3-dihydroxypropyl (meth)acrylate, polyethylene glycol mono(meth)acrylate, polypropylene glycol mono(meth)acrylate, N-vinyl-2-piperidone, N-vinyl-2-pyrrolidone, N-vinyl-6-hexanelactam, N-vinyl-3-methyl-2-pyrrolidone, N-vinyl-3-methyl-2-piperidone, N-vinyl-3-methyl-6-hexanelactam, N-vinyl-4-methyl-2-pyrrolidone, N-vinyl-4-methyl-2-piperidone, N-vinyl-4-methyl-6-hexanelactam, N-vinyl-5-methyl-2-pyrrolidone, N-vinyl-5-methyl-2-piperidone, N-vinyl-5-methyl-6-hexanelactam, N-vinyl-6-methyl-6-hexanelactam, N-vinyl-3-ethyl-2-pyrrolidone, N-vinyl-4,5-dimethyl-2-pyrrolidone, N-vinyl-5,5-dimethyl-2-pyrrolidone, (meth)acrylamide, N,N-dimethyl(meth)acrylamide, N,N-diethyl(meth)acrylamide, N-hydroxymethyl(meth)acrylamide, N-(2-hydroxyethyl)(meth)acrylamide, diacetone (meth)acrylamide, N-vinylsuccinimide, N-vinylmaleimide, N-vinylformamide, N-vinylacetamide; 3-methylene-2-pyrrolidone, maleic anhydride, and mixtures thereof.
- 5. The method of claim 1, wherein said hydrophilic polymer has a weight average molecular weight of 500 to 1,000,000.
- 6. The method of claim 1, which comprises: (a) 1 to 90 parts by weight of said hydrophilic polymer mainly composed of monomeric units selected from the group consisting of alkylene glycol units, vinyl monomeric units having a nondissociating hydrophilic group, and mixtures thereof, and (b) 99 to 10 parts by weight of water.
- 7. The method of claim 1, wherein said monomeric units selected from the group consisting of alkylene glycol units, vinyl monomeric units having a nondissociating hydrophilic group, and mixtures thereof comprise 50 to 100 mole percent of said hydrophilic polymer.
- 8. The method of claim 1, which has viscosity of less than or equal to 50,000 cp.
- 9. The method of claim 1, wherein said ocular tissue regeneration inducer is administered to the lens capsule, the vitreous body, or the cornea, of said subject in need thereof.
- 10. The method of claim 1, wherein said ocular tissue regeneration inducer is administered to the lens capsule, of said subject in need thereof.
- 11. The method of claim 1, wherein said ocular tissue regeneration inducer induces regeneration of a crystalline lens of said subject in need thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2000-015380 |
Jan 2000 |
JP |
|
CROSS REFERENCES TO RELATED APPLICATIONS
This application claims priority to Japanese Patent Application No. 2000-15380, filed on Jan. 25, 2000, the entire content of which is incorporated herein by reference, the same as set forth at length.
US Referenced Citations (11)
Foreign Referenced Citations (5)
Number |
Date |
Country |
0 641 563 |
Mar 1995 |
EP |
0641563 |
Aug 1995 |
EP |
02255151 |
Oct 1990 |
JP |
403106814 |
May 1991 |
JP |
05-117399 |
May 1992 |
JP |